Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:HYFT

MindWalk Q3 2026 Earnings Report

MindWalk logo
$1.68 -0.17 (-9.19%)
Closing price 04:00 PM Eastern
Extended Trading
$1.73 +0.05 (+2.98%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

MindWalk EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

MindWalk Revenue Results

Actual Revenue
$3.00 million
Expected Revenue
$3.50 million
Beat/Miss
Missed by -$500.00 thousand
YoY Revenue Growth
N/A

MindWalk Announcement Details

Quarter
Q3 2026
Date
3/12/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

MindWalk Earnings Headlines

MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of ...
June 2 at 9:27 AM  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/mindwalks-preclinical-dengue-data-support-112000884.html
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns
June 2 at 7:20 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260602948506/en/mindwalks-preclinical-dengue-data-support-a-hyft%c2%ae-computational-prediction-immunogens-designed-on-the-predicted-target-elicited-cross-reactive-antibodies-against-antigens-of-all-four-dengue-serotypes-reproduced-across-two-independent-campaigns/
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.tc pixel
June 5 at 1:00 AM  |  Brownstone Research (Ad)
MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage
May 27, 2026  |  financialpost.comF
MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage
May 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260527647746/en/mindwalk-holdings-deploys-pandemic-response-platform-via-hyft%c2%ae-technology-as-ebola-and-hantavirus-outbreaks-expose-the-limits-of-strain-specific-coverage/
Mindwalk Holdings Corp. Share Price (HYFT.US)
May 20, 2026  |  lse.co.ukhttps://www.lse.co.uk/SharePrice.html?shareprice=HYFT.US
See More MindWalk Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MindWalk? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MindWalk and other key companies, straight to your email.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

View MindWalk Profile
Earnings Tools